Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 8/20 | 0.36 |
| ▸ | INPP5A | Q14642 | 4/20 | 0.36 |
| ▸ | INPP5B | P32019 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172260 | 1.00 | INPPL1 (0.36) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL4172265 | 0.85 | TDP1 (0.38) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL4186933 | 0.85 | TDP1 (0.38) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL28746864 | 0.83 | INPPL1 (0.37) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL4181366 | 0.77 | FDPS (0.50) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL5606361 | 0.76 | INPPL1 (0.43) | INPPL1INPP5AINPP5BTDP1 | |
| SCHEMBL4181363 | 0.74 | FDPS (0.38) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL6679863 | 0.72 | INPPL1 (0.36) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL4186090 | 0.71 | TDP1 (0.38) | INPPL1INPP5AINPP5BFDPSBLM | |
| SCHEMBL4181918 | 0.69 | INPPL1 (0.45) | INPPL1INPP5AINPP5BFDPSBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098589-A1 | Method | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2009-04-16 | — | — | US | claimed |
| JP-2008545385-A | — | — | 2008-12-18 | — | — | JP | claimed |
| EP-1888771-A2 | METHOD FOR DETERMINING PHYTASE ACTIVITY | DANISCO A/S (DK) | 2008-02-20 | — | — | EP | claimed |
| WO-2006123254-A2 | METHOD FOR DETERMINING PHYTASE ACTIVITY | DANISCO A/S (DK) | 2006-11-23 | — | — | WO | claimed |
| US-20090098589-A1 | Method | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-1888771-A2 | METHOD FOR DETERMINING PHYTASE ACTIVITY | DANISCO A/S (DK) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123254-A2 | METHOD FOR DETERMINING PHYTASE ACTIVITY | DANISCO A/S (DK) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098589-A1 | Method | ALPL, PPA1, ITPA | INPPL1 40/4885INPP5A 15/4885INPP5B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.